Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.61 |
| ▸ | GSK3B | P49841 | 6/20 | 0.57 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.42 |
| ▸ | TCF4 | P15884 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15381299 | 1.00 | CDK2 (0.61) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL14598761 | 0.93 | CDK2 (0.64) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13119466 | 0.93 | CDK2 (0.64) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13119651 | 0.93 | CDK2 (0.57) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL15576816 | 0.89 | CDK2 (0.61) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13119345 | 0.89 | CDK2 (0.61) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13119523 | 0.88 | CDK2 (0.68) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL14562148 | 0.88 | CDK2 (0.60) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13120252 | 0.86 | CDK2 (0.55) | CDK2GSK3BMAP4K1 | |
| SCHEMBL13120122 | 0.84 | CDK2 (0.54) | CDK2GSK3BMAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673924-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673924-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8586576-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-19 | — | — | US | disclosed |
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-7196078-B2 | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPOARTION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196078-B2 | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPOARTION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |